- Home
- DMTK
DMTK
DermTech Inc.
as 05-20-2024 4:00pm EST
$.
-
$.
-.%
DermTech Inc is an emerging growth molecular diagnostic company. The company is engaged in marketing and developing novel non-invasive genomic tests to aid in the diagnosis of various skin conditions, including skin cancer, inflammatory diseases, and aging-related conditions. While the company generates revenue through laboratory services.
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 21.8M | IPO Year: | N/A |
| Target Price: | $1.38 | AVG Volume (30 days): | 299.2K |
| Analyst Decision: | Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.68 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.31 - $3.90 | Next Earning Date: | 05-14-2024 |
| Revenue: | $15,664,000 | Revenue Growth: | 9.71% |
| Revenue Growth (this year): | 19.74% | Revenue Growth (next year): | 19.86% |
Share on Social Networks:
Latest DermTech Inc. News
DMTK Breaking Stock News: Dive into DMTK Ticker-Specific Updates for Smart Investing
Business Wire
6 days ago
DermTech Reports First-Quarter 2024 Financial Results
MedTech Dive
a month ago
Cancer test maker Dermtech to cut 100 jobs, explore strategic options
Business Wire
a month ago
DermTech to Explore Strategic Alternatives and Implement Restructuring Plan
Business Wire
2 months ago
DermTech Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire
2 months ago
DermTech Presents Research Abstracts at the 2024 American Academy of Dermatology (AAD) Annual Meeting and New Research Published in the Journal of Investigative Dermatology
Simply Wall St.
3 months ago
DermTech, Inc. (NASDAQ:DMTK) Analysts Are Cutting Their Estimates: Here's What You Need To Know
Insider Monkey
3 months ago
DermTech, Inc. (NASDAQ:DMTK) Q4 2023 Earnings Call Transcript
Zacks
3 months ago